Parameters of acceptability, compliance and efficacy of fulvestrant in post-menopausal patients with advance breast cancer - FRAME
Study identifier:NIS-OAR-FAS-2008/1
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
Non-interventional report on parameters of acceptability, efficacy and compliance of fulvestrant in post-menopausal patients with advanced breast cancer HR positive who progresses to one prior endocrine therapy with antiestrogens
Medical condition
Breast Cancer
Phase
-
Healthy volunteers
No
Study drug
-
Sex
Female
Actual Enrollment
500
Study type
Observational
Age
18 Years +
Date
Study Start Date: 01 Apr 2009
Primary Completion Date: 01 Dec 2010
Study Completion Date: 01 Dec 2010
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
